Zydus Lifesciences Ltd. - Research Center
532321 ZYDUSLIFE Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
P&L
|
| More |
Profit loss account
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Income | |||||
| Operating income | 8,731.60 | 7,981.90 | 7,780.00 | 6,347.40 | 6,037.40 |
| Expenses | |||||
| Material consumed | 3,362.80 | 3,095.10 | 2,577.60 | 2,145.50 | 2,065.30 |
| Manufacturing expenses | 278.60 | 245.20 | 193.20 | 208.40 | 200.20 |
| Personnel expenses | 1,321.90 | 1,204.90 | 1,147.30 | 1,077.40 | 961.20 |
| Selling expenses | - | - | - | - | - |
| Adminstrative expenses | 1,313.90 | 1,518.60 | 1,553.20 | 1,493.00 | 1,180.90 |
| Expenses capitalised | - | - | - | - | - |
| Cost of sales | 6,277.20 | 6,063.80 | 5,471.30 | 4,924.30 | 4,407.60 |
| Operating profit | 2,454.40 | 1,918.10 | 2,308.70 | 1,423.10 | 1,629.80 |
| Other recurring income | 548.40 | 178.70 | 89.30 | 849.40 | 559.30 |
| Adjusted PBDIT | 3,002.80 | 2,096.80 | 2,398.00 | 2,272.50 | 2,189.10 |
| Financial expenses | 278.20 | 134.90 | 70.90 | 233.90 | 89.60 |
| Depreciation | 488.60 | 478.70 | 451.10 | 428.90 | 358.20 |
| Other write offs | - | - | - | - | - |
| Adjusted PBT | 2,236.00 | 1,483.20 | 1,876.00 | 1,609.70 | 1,741.30 |
| Tax charges | 503.00 | 306.00 | 212.30 | 204.10 | 301.50 |
| Adjusted PAT | 1,733.00 | 1,177.20 | 1,663.70 | 1,405.60 | 1,439.80 |
| Non recurring items | -202.00 | -318.60 | -202.80 | 2.00 | 42.10 |
| Other non cash adjustments | - | - | - | - | - |
| Reported net profit | 1,531.00 | 858.60 | 1,460.90 | 1,407.60 | 1,481.90 |
| Earnigs before appropriation | 10,820.40 | 9,655.50 | 8,796.90 | 8,053.30 | 7,004.90 |
| Equity dividend | 253.00 | 358.50 | - | 715.90 | 357.40 |
| Preference dividend | - | - | - | - | - |
| Dividend tax | - | - | - | 0.70 | 0.90 |
| Retained earnings | 10,567.40 | 9,297.00 | 8,796.90 | 7,336.70 | 6,646.60 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis